AI Verdict
MGNI has stronger fundamentals based on our AI analysis.
MGNI vs MGX Fundamental Comparison
| Metric | MGNI | MGX |
|---|---|---|
| Revenue | $714.0M | $25.2M |
| Net Income | $144.6M | $-87.9M |
| Net Margin | 20.3% | -348.5% |
| ROE | 15.7% | -55.4% |
| ROA | 4.6% | -39.7% |
| Current Ratio | 1.02x | 7.22x |
| Debt/Equity | 0.60x | 0.00x |
| EPS | $0.95 | $-2.36 |
Green = Better metric | Red = Weaker metric
You Might Also Compare
MGNI vs MGX: Frequently Asked Questions
Is MGNI or MGX a better buy in 2026?
Based on dual AI fundamental analysis (Claude and ChatGPT), MGNI has stronger fundamentals. MGNI is rated BUY (72% confidence) while MGX is rated STRONG SELL (92% confidence). This is not investment advice.
How does MGNI compare to MGX fundamentally?
MAGNITE, INC. has ROE of 15.7% vs Metagenomi Therapeutics, Inc.'s -55.4%. Net margins are 20.3% vs -348.5% respectively.
Which stock pays higher dividends, MGNI or MGX?
MGNI has a dividend yield of N/A or no dividend while MGX has N/A or no dividend. Check individual stock pages for detailed dividend history and payout ratios.
Should I invest in MGNI or MGX for long term?
For long-term investing, consider that MGNI has BUY rating with 72% confidence, while MGX has STRONG SELL rating with 92% confidence. Higher confidence indicates more consistent fundamentals from SEC filings. This is not investment advice - always do your own research.
What do the AI models say about MGNI vs MGX?
Our dual AI system (Claude by Anthropic and ChatGPT by OpenAI) analyzes SEC 10-K and 10-Q filings independently. For MGNI vs MGX, the AI consensus favors MGNI based on fundamental metrics including revenue growth, profitability, ROE, and balance sheet strength.